Aclarion, Inc. Files 8-K for Material Agreement
Ticker: ACONW · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1635077
| Field | Detail |
|---|---|
| Company | Aclarion, INC. (ACONW) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.29, $116,000, $29.68 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, financials
Related Tickers: ACON
TL;DR
ACON signed a big deal, filing shows financial details.
AI Summary
On August 12, 2024, Aclarion, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement. The company, formerly known as Nocimed, Inc., is incorporated in Delaware and headquartered in Broomfield, Colorado.
Why It Matters
This filing indicates a significant new development or contract for Aclarion, Inc., which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.
Key Numbers
- 001-41358 — SEC File Number (Identifies Aclarion, Inc.'s filing with the SEC.)
- 47-3324725 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aclarion, Inc. (company) — Registrant
- Nocimed, Inc. (company) — Former company name
- August 12, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Broomfield, Colorado (location) — Business address
FAQ
What is the nature of the material definitive agreement entered into by Aclarion, Inc. on August 12, 2024?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into.
What are the key financial details included in this 8-K filing?
The filing states that financial statements and exhibits are included, but specific financial figures are not detailed in the provided text.
When did Aclarion, Inc. change its name from Nocimed, Inc.?
The date of the name change from Nocimed, Inc. to Aclarion, Inc. was February 26, 2015.
Where is Aclarion, Inc. headquartered?
Aclarion, Inc. is headquartered at 8181 Arista Place, Suite 100, Broomfield, Colorado 80021.
What is the SIC code for Aclarion, Inc.?
The Standard Industrial Classification (SIC) code for Aclarion, Inc. is 8071, which falls under SERVICES-MEDICAL LABORATORIES.
Filing Stats: 649 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-08-12 16:02:13
Key Financial Figures
- $0.29 — mmon Stock of the Company at a price of $0.29 per share for gross proceeds to the Com
- $116,000 — re for gross proceeds to the Company of $116,000. The Shares to be issued in the offeri
- $29.68 million — itional proceeds of up to approximately $29.68 million on the same terms and conditions pursua
Filing Documents
- acon_8k.htm (8-K) — 33KB
- 0001683168-24-005494.txt ( ) — 248KB
- acon-20240812.xsd (EX-101.SCH) — 4KB
- acon-20240812_def.xml (EX-101.DEF) — 26KB
- acon-20240812_lab.xml (EX-101.LAB) — 36KB
- acon-20240812_pre.xml (EX-101.PRE) — 25KB
- acon_8k_htm.xml (XML) — 6KB
01 Entry into
Item 1.01 Entry into a Material Definitive Agreement. On August 12, 2024, Aclarion, Inc. (the "Company"), entered into a subscription agreement with an institutional investor, pursuant to which the Company agreed to issue and sell to the investor 400,000 shares (the "Shares") of Common Stock of the Company at a price of $0.29 per share for gross proceeds to the Company of $116,000. The Shares to be issued in the offering were offered at-the-market under Nasdaq rules and pursuant to the Company's Form 1-A (the "Offering Statement"), initially filed by the Company with the Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the "Securities Act"), on June 11, 2024 and qualified on June 24, 2024. The Shares were not placed through the efforts of a placement agent and no fees or commissions are to be paid on the transaction to anyone. The Company has the ability, at its election, to raise additional proceeds of up to approximately $29.68 million on the same terms and conditions pursuant to the Offering Statement. Any additional sales made pursuant to the Offering Statement will be disclosed through subsequent Prospectus Supplements. Notwithstanding that the Company desires to consummate one or more additional sales in the future, at this time the Company has no such additional oral or written agreements to consummate any such sales, and, as such, we cannot guarantee that any such sales will occur in the future.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Form of Subscription Agreement (Incorporated by reference to Exhibit 4.1 to the Company's Form 1-A/A Offering Statement filed on June 20, 2024) 104 Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARION, INC. August 12, 2024 By: /s/ John Lorbiecki Name: John Lorbiecki Title: Chief Financial Officer 3